MCID: KLT001
MIFTS: 49

Klatskin's Tumor

Categories: Rare diseases, Liver diseases, Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Klatskin's Tumor

MalaCards integrated aliases for Klatskin's Tumor:

Name: Klatskin's Tumor 12 53 15
Klatskin Tumor 12 53 59 44 73
Perihilar Cholangiocarcinoma 53 73
Hilar Cholangiocarcinoma 12 59
Perihilar Extrahepatic Bile Duct Carcinoma 12
Hilar Cca 59

Characteristics:

Orphanet epidemiological data:

59
klatskin tumor
Inheritance: Not applicable; Age of onset: Adult; Age of death: adult;

Classifications:

Orphanet: 59  
Rare hepatic diseases


External Ids:

Disease Ontology 12 DOID:4927
MeSH 44 D018285
NCIt 50 C36077
SNOMED-CT 68 253017000 6492006
Orphanet 59 ORPHA99978
ICD10 via Orphanet 34 C24.0
MESH via Orphanet 45 D018285
UMLS via Orphanet 74 C0206702

Summaries for Klatskin's Tumor

NIH Rare Diseases : 53 Klatskin tumors are are a type of cholangiocarcinoma that begins in an area called the hilum, where the left and right bile ducts join and leave the liver. It is the most common type of cholangiocarcinoma, accounting for more than half of all cases. Symptoms usually don't present until advanced stages of disease, when jaundice is the most common feature. Other symptoms include abdominal pain, unintentional weight loss, and a general feeling of being unwell (malaise).  The cause of Klatskin tumors is unknown. Studies suggest that a combination of genetic, environmental, and lifestyle factors (multifactorial) likely influence whether a person will develop cholangiocarcinoma. Because Klatskin tumors are often discovered after they have spread, they can be challenging to treat. Surgical removal of the tumor and relief of bile duct blockage are the main goals of treatment.

MalaCards based summary : Klatskin's Tumor, also known as klatskin tumor, is related to cholangiocarcinoma and extracranial arteriovenous malformation, and has symptoms including abdominal pain, icterus and malaise. An important gene associated with Klatskin's Tumor is MIR373 (MicroRNA 373
miR-373 is a methylation-mediated gene and the implication of MBD2 in methylation-mediated suppression of miR-373 plays an important role in tumourigenesis and development in hilar cholangiocarcinoma. Taqman microRNA assay shows that down-regulation of miR-373 is closely associated with poor cell differentiation, advanced clinical stage and shorter overall and disease-free survival in hilar cholangiocarcinomas. Methylation analysis shows that the promoter-associated CpG island is hypermethylated which is consistent with the inhibition of miR-373. Chromatin immunoprecipitation (ChIP) assay indicates that down-regulation of miR-373 resultes from the selective recruitment of MBD2 to methylated CpG islands. ), and among its related pathways/superpathways are MicroRNAs in cancer and Proteoglycans in cancer. The drugs Bilirubin and Bismuth have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and colon, and related phenotypes are jaundice and weight loss

Wikipedia : 76 A Klatskin tumor (or hilar cholangiocarcinoma) is a cholangiocarcinoma (cancer of the biliary tree)... more...

Related Diseases for Klatskin's Tumor

Diseases related to Klatskin's Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 85)
# Related Disease Score Top Affiliating Genes
1 cholangiocarcinoma 30.0 ALB MALAT1 MIR373 MMP2 MMP9
2 extracranial arteriovenous malformation 10.7 MMP2 MMP9
3 focal myositis 10.7 MMP2 MMP9
4 spastic entropion 10.7 MMP2 MMP9
5 lentigo maligna melanoma 10.7 MMP2 MMP9
6 villous adenocarcinoma 10.7 MMP2 MMP9
7 psammomatous meningioma 10.7 MMP2 MMP9
8 acute transverse myelitis 10.7 MMP2 MMP9
9 senile ectropion 10.6 MMP2 MMP9
10 internal hemorrhoid 10.6 MMP2 MMP9
11 ischemic colitis 10.6 MMP2 MMP9
12 conjunctival nevus 10.6 MMP2 MMP9
13 multicentric osteolysis, nodulosis, and arthropathy 10.6 MMP14 MMP2
14 microcystic meningioma 10.6 MMP2 MMP9
15 winchester syndrome 10.6 MMP14 MMP2
16 adenomyosis 10.6 MMP2 MMP9
17 corneal ulcer 10.6 MMP2 MMP9
18 nasal cavity squamous cell carcinoma 10.6 MMP2 MMP9
19 odontogenic myxoma 10.6 MMP2 MMP9
20 transverse myelitis 10.6 MMP2 MMP9
21 sorsby fundus dystrophy 10.5 MMP2 MMP9
22 lung giant cell carcinoma 10.5 MMP2 MMP9
23 hypertensive heart disease 10.5 MMP2 MMP9
24 aortic aneurysm, familial thoracic 1 10.5 MMP2 MMP9
25 nodular malignant melanoma 10.5 MMP14 MMP2
26 pneumothorax 10.4 MMP2 MMP9
27 actinic keratosis 10.4 MMP14 MMP2
28 serous cystadenocarcinoma 10.3 MMP14 MMP2
29 hepatitis 10.3
30 light chain deposition disease 10.3 MMP14 MMP2 MMP9
31 aortic aneurysm, familial abdominal, 1 10.2 MMP14 MMP2 MMP9
32 salivary gland cancer 10.2 MMP2 MMP9
33 sclerosing cholangitis 10.2
34 intrahepatic cholangiocarcinoma 10.2
35 cholangitis 10.2
36 keratoconus 10.2 MMP14 MMP2 MMP9
37 tongue cancer 10.2 MALAT1 MMP2 MMP9
38 aortic disease 10.1 MMP2 MMP9
39 appendicitis 10.1 ALB MMP9
40 tongue squamous cell carcinoma 10.1 MALAT1 MMP2 MMP9
41 microvascular complications of diabetes 3 10.1 ALB MALAT1
42 parotitis 10.1 ALB MMP2 MMP9
43 adamantinoma of long bones 10.1 MALAT1 MMP2 MMP9
44 severe pre-eclampsia 10.1 ALB MMP9
45 cholangitis, primary sclerosing 10.0
46 adenocarcinoma 10.0
47 pancreatitis 10.0
48 type i 10.0
49 lung cancer susceptibility 3 10.0 MALAT1 MMP2 MMP9
50 renal cell carcinoma, nonpapillary 10.0 MALAT1 MMP2 MMP9

Graphical network of the top 20 diseases related to Klatskin's Tumor:



Diseases related to Klatskin's Tumor

Symptoms & Phenotypes for Klatskin's Tumor

Human phenotypes related to Klatskin's Tumor:

59 32 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 jaundice 59 32 hallmark (90%) Very frequent (99-80%) HP:0000952
2 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
3 fever 59 32 occasional (7.5%) Occasional (29-5%) HP:0001945
4 abdominal pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002027
5 hepatomegaly 59 32 frequent (33%) Frequent (79-30%) HP:0002240
6 lymphadenopathy 59 32 frequent (33%) Frequent (79-30%) HP:0002716
7 venous thrombosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0004936
8 extrahepatic cholestasis 59 32 hallmark (90%) Very frequent (99-80%) HP:0012334
9 fatigue 59 32 occasional (7.5%) Occasional (29-5%) HP:0012378
10 cholangiocarcinoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0030153

UMLS symptoms related to Klatskin's Tumor:


abdominal pain, icterus, malaise

Drugs & Therapeutics for Klatskin's Tumor

Drugs for Klatskin's Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bilirubin Phase 4 635-65-4 5280352
2
Bismuth Phase 4 7440-69-9 16682734 105143
3
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
5
Trioxsalen Approved Phase 3,Not Applicable 3902-71-4 5585
6 Dermatologic Agents Phase 3,Phase 2,Not Applicable
7 Photosensitizing Agents Phase 3,Phase 2,Not Applicable
8 Liver Extracts Phase 2, Phase 3,Phase 1,Not Applicable
9 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
10 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
11 Ether Phase 3,Not Applicable
12
s 1 (combination) Phase 3
13 Hematoporphyrin Derivative Phase 3,Not Applicable
14 Hematoporphyrins Phase 3,Not Applicable
15 Dihematoporphyrin Ether Phase 3,Not Applicable
16 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
17 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
18 Antiviral Agents Phase 3,Phase 2,Phase 1
19
Capecitabine Approved, Investigational Phase 2,Phase 1,Not Applicable 154361-50-9 60953
20
Fluorouracil Approved Phase 2,Not Applicable 51-21-8 3385
21
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
22
Trametinib Approved Phase 2 871700-17-3 11707110
23
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
24
Temoporfin Approved, Investigational Phase 2 122341-38-2
25
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
26
Ceritinib Approved Phase 2 1032900-25-6
27
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
28
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
29
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
31 Hematinics Phase 1, Phase 2,Phase 2,Not Applicable
32
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
33 Micronutrients Phase 2
34 Nicotinic Acids Phase 2
35 Trace Elements Phase 2
36 Vitamin B Complex Phase 2
37 Vitamins Phase 2
38 Antidotes Phase 2
39 Protective Agents Phase 2
40 Protein Kinase Inhibitors Phase 2
41 Bone Density Conservation Agents Phase 2
42 Calcium, Dietary Phase 2
43 Anti-Inflammatory Agents Phase 2
44 Folate Nutraceutical Phase 2
45 Vitamin B3 Nutraceutical Phase 2
46 Vitamin B9 Nutraceutical Phase 2
47
Menthol Approved Not Applicable 2216-51-5 16666
48
Cefoxitin Approved Not Applicable 35607-66-0 441199
49
Cefotaxime Approved Not Applicable 63527-52-6 456256 5742673
50
Epinephrine Approved, Vet_approved Not Applicable 51-43-4 5816

Interventional clinical trials:

(show all 43)
# Name Status NCT ID Phase Drugs
1 Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent Unknown status NCT00746538 Phase 4
2 Preoperative Biliary Drainage for Resectable Hilar Cholangiocarcinoma Unknown status NCT00797121 Phase 4
3 Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture Unknown status NCT01125865 Phase 4
4 Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Hilar Cholangiocarcinoma Completed NCT00721175 Phase 4
5 Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma Unknown status NCT02108145 Phase 2, Phase 3
6 S-1 and Photodynamic Therapy in Cholangiocarcinoma Completed NCT00869635 Phase 3 S-1 Chemotherapy
7 Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS) Terminated NCT02082522 Phase 3 Photodynamic therapy-Photofrin;Chemotherapy regimen
8 Safety Study of Liver Transplantation for Hilar Cholangiocarcinoma Unknown status NCT02178280 Phase 1, Phase 2
9 Photodynamic Therapy in Locally Advanced Hilar Cholangiocarcinoma Unknown status NCT02725073 Phase 2
10 Regorafenib Versus Placebo to Treat Cholangiocarcinoma Unknown status NCT02162914 Phase 2 Regorafenib/active;Regorafenib/placebo
11 Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Completed NCT02042443 Phase 2 Capecitabine;Fluorouracil;Leucovorin Calcium;Trametinib
12 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT01093222 Phase 2 Erlotinib Hydrochloride;Sorafenib Tosylate
13 Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar Cholangiocarcinoma Recruiting NCT02955771 Phase 2
14 Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers Recruiting NCT03003065 Phase 2 Temoporfin
15 A Study of ABC294640 (Yeliva ®) in the Treatment of Patients With Advanced Cholangiocarcinoma Recruiting NCT03377179 Phase 2 ABC294640
16 A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma Terminated NCT02374489 Phase 2 LDK378
17 Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation Terminated NCT01151761 Phase 2 Gemcitabine;Cisplatin;Carboplatin;Capecitabine;5FU
18 ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed by Surgery Completed NCT01825603 Phase 1 ADH-1;Cisplatin;Gemcitabine Hydrochloride
19 Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor) Terminated NCT00630890 Phase 1
20 Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma Withdrawn NCT02856568 Phase 1 Cisplatin;Gemcitabine Hydrochloride;Ricolinostat
21 Liver Transplantation for Hilar Cholangiocarcinoma in Association With Neoadjuvant Radio- and Chemo-therapy Unknown status NCT01549795 Not Applicable Capecitabine
22 Best Biliary Drainage Option in Advanced Klatskin Tumor Completed NCT03104582 Not Applicable
23 Surgical Treatment of Hilar Cholangiocarcinoma: Minor or Major Liver Resection? Completed NCT00733200 Not Applicable
24 Single Versus Multiple Deployment of Metallic Stents for Inoperable Malignant Hilar Biliary Obstruction Completed NCT02166970 Not Applicable
25 The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma Completed NCT01673802 Early Phase 1 CT scan
26 Photodynamic Therapy With Polyhematoporphyrin for Malignant Biliary Obstruction Completed NCT02504957 Not Applicable
27 RALPPS in Patients With Hilar and Intrahepatic Cholangiocarcinoma Completed NCT03320980
28 Safety and Efficacy of Photodynamic Therapy for Bile Duct Invasion of Hepatocellular Carcinoma Completed NCT01506115 Not Applicable Photofrin
29 Stereotactic Body Radiation Therapy for Unresectable Perihilar Cholangiocarcinoma Recruiting NCT03307538 Not Applicable
30 Impact of Three-dimensional Visualization on Operation Strategy and Complications for Hilar Cholangiocarcinoma Recruiting NCT03132649
31 Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma Recruiting NCT03104569 Not Applicable
32 Liver Resection Versus Radio-chemotherapy-Transplantation for Hilar Cholangiocarcinoma Recruiting NCT02232932 Not Applicable
33 Application of Endoscopic Scissors Cutting ENBD Tube in the Treatment of Malignant Hilar Biliary Strictures Recruiting NCT03353181 Not Applicable
34 A Trial of Percutaneous vs. Endoscopic Drainage of Suspected Klatskin Tumors Recruiting NCT03172832 Not Applicable
35 Superior Bilioenteric Anastomosis by Magnetic Compressive Technique Recruiting NCT02801500 Not Applicable
36 Effectiveness of Prophylactic Antibiotics to Prevent Post Endoscopic Retrograde Cholangio Pancreatography Bacteremia in Biliary Obstruction Patient Recruiting NCT02958059 Not Applicable
37 Comparing Three Dimension Laparoscopic Versus Open Surgery for Perihiliar Cholangiocarcinoma Recruiting NCT03383796 Not Applicable
38 Efficacy and Tolerability of Hemopatch After Hepatic Resection Recruiting NCT03323359 Not Applicable
39 Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®) Available NCT03414489 ABC294640
40 Optimization of Health Expenditure in Liver Surgery Enrolling by invitation NCT01715402
41 Process Optimization of Preoperative Biliary Drainage in Patients With Malignant Obstructive Jaundice Not yet recruiting NCT03527875 Not Applicable
42 Liver Transplantation for Cholangiocarcinoma Terminated NCT00708877 Not Applicable
43 Coregistration of 18F-FDG-PET and MRI in the Staging of Potentially Resectable Hilar Cholangiocarcinoma: a Pilot Study Withdrawn NCT00604266

Search NIH Clinical Center for Klatskin's Tumor

Cochrane evidence based reviews: klatskin tumor

Genetic Tests for Klatskin's Tumor

Anatomical Context for Klatskin's Tumor

MalaCards organs/tissues related to Klatskin's Tumor:

41
Liver, Bone, Colon

Publications for Klatskin's Tumor

Articles related to Klatskin's Tumor:

(show all 33)
# Title Authors Year
1
Primary large cell neuroendocrine carcinoma of the common hepatic duct mimicking a Klatskin tumor. ( 29466852 )
2018
2
Primary extrahepatic bile duct neuroendocrine tumor with obstructive jaundice masquerading as a Klatskin tumor. ( 28596824 )
2017
3
Primary extrahepatic bile duct lymphoma mimicking Klatskin's tumor, dramatic response to chemotherapy. ( 25681815 )
2015
4
Metachronous Ampulla of Vater Carcinoma after Curative-Intent Surgery for Klatskin Tumor. ( 26305204 )
2015
5
Metastasis-associated in colon cancer 1 is an independent prognostic biomarker for survival in Klatskin tumor patients. ( 25953673 )
2015
6
An unresectable Klatskin's tumor? ( 24780210 )
2014
7
[Perihilar cholangiocarcinoma (Klatskin tumor)]. ( 24464335 )
2014
8
Surgical strategies in patients with advanced hilar cholangiocarcinoma (Klatskin tumor). ( 23242846 )
2013
9
Extrahepatic biliary cystadenocarcinoma mimicking Klatskin tumor. ( 23702875 )
2013
10
Spindle-cell variant of primary cutaneous follicle center lymphoma spreading to the hepatobiliary tree, mimicking Klatskin tumor. ( 23167279 )
2013
11
Autoimmune cholangitis mimicking a klatskin tumor: a case report. ( 21955859 )
2011
12
Biliary Actinomycosis Mimicking a Klatskin Tumor. ( 21766219 )
2011
13
Multidisciplinary management of hilar cholangiocarcinoma (Klatskin tumor): extended resection is associated with improved survival. ( 21115233 )
2011
14
Portal vein encasement complicates resection of Klatskin's tumor. ( 20135922 )
2010
15
[A case of undifferentiated (embryonal) liver sarcoma mimicking klatskin tumor in an adult]. ( 20168062 )
2010
16
Primary neuroendocrine tumor of the extrahepatic biliary tree mimicking Klatskin tumor. ( 20922208 )
2010
17
[Hilar cholangiocarcinoma (Klatskin's tumor): up-to-date radiologic diagnosis, intervention and treatment possibilities]. ( 19401964 )
2009
18
The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis. ( 19330734 )
2009
19
Metallothionein overexpression and its prognostic relevance in intrahepatic cholangiocarcinoma and extrahepatic hilar cholangiocarcinoma (Klatskin tumors). ( 19683330 )
2009
20
Hepatic tuberculosis mimicking Klatskin tumor: a diagnostic dilemma. ( 18723964 )
2008
21
Actual long-term outcome of Klatskin's tumor after surgical resection. ( 19260464 )
2008
22
Extrahepatic bile duct neurilemmoma mimicking Klatskin tumor. ( 17367238 )
2007
23
Optimal biliary drainage for inoperable Klatskin's tumor based on Bismuth type. ( 17663508 )
2007
24
Liver transplantation for Klatskin's tumor: contraindicated, palliative, or indicated? ( 17889167 )
2007
25
Detection of Klatskin's tumor in extrahepatic bile duct strictures using delayed 18F-FDG PET/CT: preliminary results for 22 patient studies. ( 16000285 )
2005
26
Concomitant sclerosing mesenteritis and bile duct fibrosis simulating Klatskin's tumor. ( 12086905 )
2001
27
Klatskin's tumor: is there new hope? ( 11120299 )
2000
28
Granular cell tumor at the hepatic duct confluence mimicking Klatskin tumor. A report of two cases and a review of the literature. ( 10867472 )
2000
29
Multiple stents in treatment of obstructive jaundice associated with Klatskin's tumor. ( 10470950 )
1999
30
Long-term survival after resection of proximal bile duct carcinoma (Klatskin tumors). ( 9841770 )
1999
31
Liver transplantation in the management of Klatskin's tumor. ( 10500686 )
1999
32
Intraluminal endocurietherapy of inoperable Klatskin's tumor with high-activity 192iridium. ( 3775068 )
1986
33
Clinical conferences at the Johns Hopkins Hospital. Klatskin tumor: radiologic features of biliary tract disease. ( 6273640 )
1981

Variations for Klatskin's Tumor

Expression for Klatskin's Tumor

Search GEO for disease gene expression data for Klatskin's Tumor.

Pathways for Klatskin's Tumor

GO Terms for Klatskin's Tumor

Cellular components related to Klatskin's Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix GO:0031012 8.8 MMP14 MMP2 MMP9

Biological processes related to Klatskin's Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix disassembly GO:0022617 9.33 MMP14 MMP2 MMP9
2 embryo implantation GO:0007566 9.32 MMP2 MMP9
3 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.26 MMP2 MMP9
4 collagen catabolic process GO:0030574 9.13 MMP14 MMP2 MMP9
5 endodermal cell differentiation GO:0035987 8.8 MMP14 MMP2 MMP9

Molecular functions related to Klatskin's Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.33 MMP14 MMP2 MMP9
2 metallopeptidase activity GO:0008237 9.13 MMP14 MMP2 MMP9
3 metalloendopeptidase activity GO:0004222 8.8 MMP14 MMP2 MMP9

Sources for Klatskin's Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....